Sofinnova Investments, a Menlo Park, Calif.-based clinical stage biopharmaceutical investment firm, added Maha Katabi, PhD. to the investment team as a Partner.
Maha Katabi, PhD., is an experienced investor in biopharma companies, with over 18 years in venture capital investing and public equities portfolio management.
Prior to founding Oxalis in 2018, Katabi was a Partner at Sectoral Asset Management since 2008, where she formed and led a dedicated investment team and advisory board to drive investments in private companies.
Additionally, Katabi was a Portfolio Manager for a family of funds that invested in publicly listed and private healthcare companies.
Prior to Sectoral, she was Vice-President at Ventures West Management, a venture capital firm focused on technology and life sciences in Canada and the United States.
Katabi started her venture capital career in 1999 at T2C2 Capital Bio, a seed fund targeting Canadian start-ups.
With the addition of Dr. Katabi, Sofinnova will also be opening an office in Montreal, Quebec. The new location will enable the firm to work more closely with biotech companies based on the East Coast, in Europe, and in Canada.
Sofinnova will now have three offices; Menlo Park, Ca., San Diego, Ca., and Montreal, Quebec.